Schedules of Controlled Substances: DEA Update on Synthetic Cannabinoids
The DEA synthetic cannabinoids schedule I placement update designates cumyl-pegaclone as a high-risk substance with no accepted medical use. This update highlights ongoing challenges in regulating novel synthetic cannabinoids. Clinicians should be aware…
Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA synthetic ketamine schedule I placement of 2-fluorodeschloroketamine reflects urgent regulatory action on novel psychoactive substances. This temporary scheduling addresses abuse potential and lack of accepted medical use. Clinicians should stay…
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA synthetic cannabinoids schedule I placement 2026 includes MDMB-4en-PINACA, a potent synthetic cannabinoid with high abuse potential. This scheduling reflects significant clinical concerns about its adverse effects and lack of medical use.…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA synthetic cannabinoids schedule I placement 2026 update highlights the inclusion of four novel cannabinoids into Schedule I. This reflects their high abuse potential and lack of accepted medical use. Clinicians should be vigilant for synthetic…
Challenges in Regulating Synthetic Cannabinoids: Schedule I Placement
The synthetic cannabinoid regulation challenges are highlighted by the DEA's placement of CUMYL-PEGACLONE in Schedule I. This classification reflects high abuse potential and no accepted medical use. Clinicians must understand these regulatory challenges…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The Drug Enforcement Administration has enacted the temporary placement of 2-fluorodeschloroketamine in Schedule I of the Controlled Substances Act. This scheduling restricts the availability of this synthetic ketamine analog due to its high abuse…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA synthetic cannabinoids Schedule I placement 2026 update includes cumyl-pegaclone due to its high abuse potential and lack of accepted medical use. This regulatory action highlights ongoing challenges in controlling novel psychoactive substances.…
DEA Emergency Scheduling: Temporary Placement of 2-Fluorodeschloroketamine
The DEA emergency scheduling controlled substances action temporarily places 2-fluorodeschloroketamine in Schedule I due to abuse potential. This update highlights regulatory efforts to control emerging synthetic ketamine analogs. Clinicians should be…
Clinical and Regulatory Insights on MDMB-4en-PINACA Synthetic Cannabinoid
MDMB-4en-PINACA synthetic cannabinoid risks are significant due to its high potency and unpredictable effects. This substance's Schedule I classification underscores its public health dangers. Clinicians should be aware of these risks to better counsel…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA synthetic cannabinoids Schedule I placement 2026 update highlights the addition of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA. These substances pose significant public health risks due to their potency and lack of accepted…